NeoGenomics, Inc. (NEO) Earnings Call Transcripts
NeoGenomics, Inc.'s Latest Earnings Call - June 17, 2026
During the Annual General and Special Meeting of Shareholders held on June 17, 2026, Neo Performance Materials Inc. did not provide specific financial results or guidance updates. However, the meeting focused on the election of directors and the approval of various corporate resolutions, indicating stable governance and shareholder engagement. The lack of financial disclosures may lead to uncertainty among investors regarding the company's operational performance for the fiscal year.
Reported metrics
| Metric | Value |
|---|---|
| Proxies Received | 25.4 million (positive) |
| Votes in Favor of Directors | 81% to over 99% (positive) |
| Votes Against Auditor Reappointment | <5% (positive) |
| Votes Against Omnibus Plan | <5% (positive) |
| Votes Against Shareholder Rights Plan | <5% (positive) |
What management said
My name is Jonathan Baksh, and I'm a shareholder. I nominate the 6 persons whose names have been read to this meeting by the Secretary for election as directors of the company to serve until the next Annual Meeting of Shareholders to be held in 2027.
I move that each of the persons nominated be elected individually as directors of the company until the conclusion of the next Annual Meeting of Shareholders or until his or her successor is duly elected or appointed or he or she otherwise ceases to hold office.
What analysts pressed on
Analysts may be concerned about the lack of financial performance details during the meeting. The absence of revenue and earnings updates could lead to uncertainty regarding the company's operational health and future guidance.
Main topics on the call
- Director Elections — The meeting successfully elected six directors with votes in favor ranging from 81% to over 99%. This strong support reflects shareholder confidence in the current management team.
- Reappointment of Auditors — KPMG LLP was reappointed as auditors with less than 5% of votes withheld, indicating strong shareholder support for the company's financial oversight.
- Omnibus Long-Term Incentive Plan — Amendments to the company's Omnibus Long-Term Incentive Plan were approved, suggesting a commitment to aligning management incentives with shareholder interests.
- Shareholder Rights Plan — The ratification of the company's Second Amended and Restated Shareholder Rights Plan was passed, which may enhance shareholder protection against potential takeovers.
Read the full NeoGenomics, Inc. transcript (June 17, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About NeoGenomics, Inc.
NeoGenomics, Inc. (NEO) is a publicly listed company in the Health Care Providers and Services industry, within the Health Care sector. It trades on NasdaqCM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 82 calls on record spanning February 27, 2020 to September 15, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 82 NeoGenomics, Inc. earnings call transcripts on record, spanning February 27, 2020 to September 15, 2026. Based on this history, NeoGenomics, Inc. reports quarterly. The most recent call on file is dated September 15, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- NEO
- Exchange
- NasdaqCM
- Country
- US
- Sector
- Health Care
- Calls on record
- 82
- First call
- February 27, 2020
- Most recent
- September 15, 2026
- Reporting cadence
- quarterly